icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
 
 
 
New HIV 'Cure' Drug To Activate HIV Replication- Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial
 
 
  Reported by Jules Levin
IAS 2013 Kuala Lumpur June 30-July 3
 
Martin Tolstrup
Aarhus University Hospital, Denmark
 
· Panobinostat is a cinnamic hydroxamic acid analogue very similar to Vorinostat
· Panobinostat is being developed by Novartis for treatment of Multiple myeloma (Phase III) and Acute Myeloid Leukemia (Phase II)
· Panobinostat is described as a Pan-HDAC inhibitor with inhibitory activity in the lower nM range
· Considerable inhibitory activity against HDAC 1, 2 and 3
which appear important for disruption of HIV latency
 
Oral tablet 20 mg three times pr week every other week
· Repeated 4 times for a total of 8 weeks.
· Total of 12 doses
 
Would 20 mg oral Panobinostat dosing lead to viral reactivation in virological suppressed HIV-1 patients?
 
Could a cyclic dosing pattern lead to more efficient viral "kick" and reduce side effects especially thrombocytopenia?

IAS1.gif

IAS2.gif

IAS3.gif

IAS4.gif

IAS5.gif

IAS6.gif

IAS7.gif

IAS8.gif

IAS9.gif

IAS10.gif

IAS11.gif

IAS12.gif

IAS13.gif

IAS14.gif